GW0742, a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice - PubMed (original) (raw)
. 2010 Oct-Dec;23(4):1033-46.
doi: 10.1177/039463201002300408.
Affiliations
- PMID: 21244753
- DOI: 10.1177/039463201002300408
Free article
GW0742, a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice
M Galuppo et al. Int J Immunopathol Pharmacol. 2010 Oct-Dec.
Free article
Abstract
Peroxisome Proliferator-Activated Receptor β/δ belongs to a family of ligand-activated transcription factors. Recent data have clarified its metabolic roles and enhanced the potential role of this receptor as a pharmacological target. Moreover, although its role in acute inflammation remains unclear, being the nuclear receptor PPAR β/δ widely expressed in many tissues, including the vascular endothelium, we assume that the infiltration of PMNs into tissues, a prominent feature in inflammation, may also be related to PPAR β/δ. Mice subjected to intratracheal instillation of bleomycin (BLEO, 1 mg/kg), a glycopeptide produced by the bacterium Streptomyces verticillus, develop lung inflammation and injury characterized by a significant neutrophil infiltration and tissue oedema. Therefore, the aim of this study is to investigate the effects of GW0742, a synthetic high affinity PPAR β/δ agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis. Our data showed that GW0742-treatment (0.3 mg/Kg, 10 percent DMSO, i.p.) has therapeutic effects on pulmonary damage, decreasing many inflammatory and apoptotic parameters detected by measurement of: 1) cytokine production; 2) leukocyte accumulation, indirectly measured as decrease of myeloperoxidase (MPO) activity; 3) IkBα degradation and NF-kB nuclear translocation; 4) ERK phosphorylation; 5) stress oxidative by NO formation due to iNOS expression; 6) nitrotyrosine and PAR localization; 7) the degree of apoptosis, evaluated by Bax and Bcl-2 balance, FAS ligand expression and TUNEL staining. Taken together, our results clearly show that GW0742 reduces the lung injury and inflammation due to the intratracheal BLEO--instillation in mice.
Similar articles
- Evidence for the role of peroxisome proliferator-activated receptor-beta/delta in the development of spinal cord injury.
Paterniti I, Esposito E, Mazzon E, Galuppo M, Di Paola R, Bramanti P, Kapoor A, Thiemermann C, Cuzzocrea S. Paterniti I, et al. J Pharmacol Exp Ther. 2010 May;333(2):465-77. doi: 10.1124/jpet.110.165605. Epub 2010 Feb 22. J Pharmacol Exp Ther. 2010. PMID: 20176685 - GW0742, a high-affinity PPAR -beta/delta agonist, inhibits acute lung injury in mice.
Di Paola R, Crisafulli C, Mazzon E, Esposito E, Paterniti I, Galuppo M, Genovese T, Thiemermann C, Cuzzocrea S. Di Paola R, et al. Shock. 2010 Apr;33(4):426-35. doi: 10.1097/SHK.0b013e3181b8f2fb. Shock. 2010. PMID: 20407409 - Peroxisome proliferator-activated receptor β/δ agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice.
Paterniti I, Mazzon E, Riccardi L, Galuppo M, Impellizzeri D, Esposito E, Bramanti P, Cappellani A, Cuzzocrea S. Paterniti I, et al. Surgery. 2012 Jul;152(1):90-106. doi: 10.1016/j.surg.2012.02.004. Epub 2012 Apr 21. Surgery. 2012. PMID: 22521259 - Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy.
Strosznajder AK, Wójtowicz S, Jeżyna MJ, Sun GY, Strosznajder JB. Strosznajder AK, et al. Neuromolecular Med. 2021 Mar;23(1):86-98. doi: 10.1007/s12017-020-08629-9. Epub 2020 Nov 18. Neuromolecular Med. 2021. PMID: 33210212 Free PMC article. Review. - Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.
Toral M, Romero M, Pérez-Vizcaíno F, Duarte J, Jiménez R. Toral M, et al. Am J Physiol Heart Circ Physiol. 2017 Feb 1;312(2):H189-H200. doi: 10.1152/ajpheart.00155.2016. Epub 2016 Nov 23. Am J Physiol Heart Circ Physiol. 2017. PMID: 27881385 Review.
Cited by
- Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease.
Gonzales J, Fraidenburg DR. Gonzales J, et al. Pharmaceuticals (Basel). 2023 Mar 9;16(3):418. doi: 10.3390/ph16030418. Pharmaceuticals (Basel). 2023. PMID: 36986517 Free PMC article. Review. - The NFκB Antagonist CDGSH Iron-Sulfur Domain 2 Is a Promising Target for the Treatment of Neurodegenerative Diseases.
Kung WM, Lin MS. Kung WM, et al. Int J Mol Sci. 2021 Jan 19;22(2):934. doi: 10.3390/ijms22020934. Int J Mol Sci. 2021. PMID: 33477809 Free PMC article. Review. - Wild Bitter Melon Exerts Anti-Inflammatory Effects by Upregulating Injury-Attenuated CISD2 Expression following Spinal Cord Injury.
Kung WM, Lin CC, Kuo CY, Juin YC, Wu PC, Lin MS. Kung WM, et al. Behav Neurol. 2020 Sep 30;2020:1080521. doi: 10.1155/2020/1080521. eCollection 2020. Behav Neurol. 2020. PMID: 33062068 Free PMC article. - Adelmidrol: A New Promising Antioxidant and Anti-Inflammatory Therapeutic Tool in Pulmonary Fibrosis.
Fusco R, Cordaro M, Genovese T, Impellizzeri D, Siracusa R, Gugliandolo E, Peritore AF, D'Amico R, Crupi R, Cuzzocrea S, Di Paola R. Fusco R, et al. Antioxidants (Basel). 2020 Jul 9;9(7):601. doi: 10.3390/antiox9070601. Antioxidants (Basel). 2020. PMID: 32660140 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous